Original Article
Cost Effectiveness of Outpatient Asthma Clinics
Coste-efectividad de una unidad monográfica de asma
Read
7167
Timeswas read the article
2372
Total PDF
4795
Total HTML
Share statistics
array:24 [ "pii" => "S1579212916000343" "issn" => "15792129" "doi" => "10.1016/j.arbr.2016.02.009" "estado" => "S300" "fechaPublicacion" => "2016-04-01" "aid" => "1262" "copyright" => "SEPAR" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2016;52:196-203" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2780 "formatos" => array:3 [ "EPUB" => 160 "HTML" => 1977 "PDF" => 643 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0300289615003762" "issn" => "03002896" "doi" => "10.1016/j.arbres.2015.09.009" "estado" => "S300" "fechaPublicacion" => "2016-04-01" "aid" => "1262" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2016;52:196-203" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4374 "formatos" => array:3 [ "EPUB" => 143 "HTML" => 3003 "PDF" => 1228 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Coste-efectividad de una unidad monográfica de asma" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "196" "paginaFinal" => "203" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Cost Effectiveness of Outpatient Asthma Clinics" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1027 "Ancho" => 3161 "Tamanyo" => 144770 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Porcentajes de pacientes tratados con distintos medicamentos, el año previo y el año posterior a su primera visita a la UMA.</p> <p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">AntiIgE: antiinmunoglobulina E; CI/LABA: corticoide inhalado con broncodilatador de larga duración; UltraLABA: beta-agonista de 24<span class="elsevierStyleHsp" style=""></span>h de duración.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Luis A. Pérez de Llano, Renata Villoro, María Merino, Maria del Carmen Gómez Neira, Camino Muñiz, Álvaro Hidalgo" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Luis A." "apellidos" => "Pérez de Llano" ] 1 => array:2 [ "nombre" => "Renata" "apellidos" => "Villoro" ] 2 => array:2 [ "nombre" => "María" "apellidos" => "Merino" ] 3 => array:2 [ "nombre" => "Maria del Carmen" "apellidos" => "Gómez Neira" ] 4 => array:2 [ "nombre" => "Camino" "apellidos" => "Muñiz" ] 5 => array:2 [ "nombre" => "Álvaro" "apellidos" => "Hidalgo" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1579212916000343" "doi" => "10.1016/j.arbr.2016.02.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212916000343?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289615003762?idApp=UINPBA00003Z" "url" => "/03002896/0000005200000004/v1_201603270531/S0300289615003762/v1_201603270531/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1579212916000355" "issn" => "15792129" "doi" => "10.1016/j.arbr.2016.02.010" "estado" => "S300" "fechaPublicacion" => "2016-04-01" "aid" => "1267" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2016;52:204-10" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2061 "formatos" => array:3 [ "EPUB" => 152 "HTML" => 1410 "PDF" => 499 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Benchmarking in Thoracic Surgery. Third Edition" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "204" "paginaFinal" => "210" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "<span class="elsevierStyleItalic">Benchmarking</span> en cirugía torácica. Tercera edición" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1615 "Ancho" => 3209 "Tamanyo" => 245494 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Activity of participating thoracic surgery units.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jorge Freixinet Gilart, Gonzalo Varela Simó, Pedro Rodríguez Suárez, Raúl Embún Flor, Juan José Rivas de Andrés, Mercedes de la Torre Bravos, Laureano Molins López-Rodó, Joaquín Pac Ferrer, José Miguel Izquierdo Elena, Benno Baschwitz, Pedro E. López de Castro, Juan José Fibla Alfara, Florentino Hernando Trancho, Ángel Carvajal Carrasco, Emili Canalís Arrayás, Ángel Salvatierra Velázquez, Mercedes Canela Cardona, Juan Torres Lanzas, Nicolás Moreno Mata" "autores" => array:19 [ 0 => array:2 [ "nombre" => "Jorge" "apellidos" => "Freixinet Gilart" ] 1 => array:2 [ "nombre" => "Gonzalo" "apellidos" => "Varela Simó" ] 2 => array:2 [ "nombre" => "Pedro" "apellidos" => "Rodríguez Suárez" ] 3 => array:2 [ "nombre" => "Raúl" "apellidos" => "Embún Flor" ] 4 => array:2 [ "nombre" => "Juan José Rivas" "apellidos" => "de Andrés" ] 5 => array:2 [ "nombre" => "Mercedes" "apellidos" => "de la Torre Bravos" ] 6 => array:2 [ "nombre" => "Laureano" "apellidos" => "Molins López-Rodó" ] 7 => array:2 [ "nombre" => "Joaquín" "apellidos" => "Pac Ferrer" ] 8 => array:2 [ "nombre" => "José Miguel" "apellidos" => "Izquierdo Elena" ] 9 => array:2 [ "nombre" => "Benno" "apellidos" => "Baschwitz" ] 10 => array:2 [ "nombre" => "Pedro E." "apellidos" => "López de Castro" ] 11 => array:2 [ "nombre" => "Juan José" "apellidos" => "Fibla Alfara" ] 12 => array:2 [ "nombre" => "Florentino" "apellidos" => "Hernando Trancho" ] 13 => array:2 [ "nombre" => "Ángel" "apellidos" => "Carvajal Carrasco" ] 14 => array:2 [ "nombre" => "Emili" "apellidos" => "Canalís Arrayás" ] 15 => array:2 [ "nombre" => "Ángel" "apellidos" => "Salvatierra Velázquez" ] 16 => array:2 [ "nombre" => "Mercedes" "apellidos" => "Canela Cardona" ] 17 => array:2 [ "nombre" => "Juan" "apellidos" => "Torres Lanzas" ] 18 => array:2 [ "nombre" => "Nicolás" "apellidos" => "Moreno Mata" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0300289615003890" "doi" => "10.1016/j.arbres.2015.09.014" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289615003890?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212916000355?idApp=UINPBA00003Z" "url" => "/15792129/0000005200000004/v2_201604010234/S1579212916000355/v2_201604010234/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S157921291600029X" "issn" => "15792129" "doi" => "10.1016/j.arbr.2016.02.004" "estado" => "S300" "fechaPublicacion" => "2016-04-01" "aid" => "1232" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2016;52:189-95" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2815 "formatos" => array:3 [ "EPUB" => 166 "HTML" => 1940 "PDF" => 709 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Unilateral or Bilateral Thoracocentesis for Bilateral Pleural Effusion. A Prospective Study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "189" "paginaFinal" => "195" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Derrame pleural bilateral: ¿toracocentesis uni o bilateral? Estudio prospectivo" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1007 "Ancho" => 1424 "Tamanyo" => 70170 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Algorithm for study of bilateral pleural effusion. BPE: bilateral pleural effusion; BDT: bilateral diagnostic thoracocentesis.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Lucía Ferreiro, María Esther San José, Francisco Gude, Adriana Lama, Juan Suárez-Antelo, Antonio Golpe, M. Elena Toubes, Francisco Javier González-Barcala, José Manuel Álvarez-Dobaño, Luis Valdés" "autores" => array:10 [ 0 => array:2 [ "nombre" => "Lucía" "apellidos" => "Ferreiro" ] 1 => array:2 [ "nombre" => "María Esther" "apellidos" => "San José" ] 2 => array:2 [ "nombre" => "Francisco" "apellidos" => "Gude" ] 3 => array:2 [ "nombre" => "Adriana" "apellidos" => "Lama" ] 4 => array:2 [ "nombre" => "Juan" "apellidos" => "Suárez-Antelo" ] 5 => array:2 [ "nombre" => "Antonio" "apellidos" => "Golpe" ] 6 => array:2 [ "nombre" => "M. Elena" "apellidos" => "Toubes" ] 7 => array:2 [ "nombre" => "Francisco Javier" "apellidos" => "González-Barcala" ] 8 => array:2 [ "nombre" => "José Manuel" "apellidos" => "Álvarez-Dobaño" ] 9 => array:2 [ "nombre" => "Luis" "apellidos" => "Valdés" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0300289615003191" "doi" => "10.1016/j.arbres.2015.07.011" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289615003191?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S157921291600029X?idApp=UINPBA00003Z" "url" => "/15792129/0000005200000004/v2_201604010234/S157921291600029X/v2_201604010234/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Cost Effectiveness of Outpatient Asthma Clinics" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "196" "paginaFinal" => "203" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Luis A. Pérez de Llano, Renata Villoro, María Merino, Maria del Carmen Gómez Neira, Camino Muñiz, Álvaro Hidalgo" "autores" => array:6 [ 0 => array:4 [ "nombre" => "Luis A." "apellidos" => "Pérez de Llano" "email" => array:1 [ 0 => "eremos26@hotmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Renata" "apellidos" => "Villoro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "María" "apellidos" => "Merino" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Maria del Carmen Gómez" "apellidos" => "Neira" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 4 => array:3 [ "nombre" => "Camino" "apellidos" => "Muñiz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "Álvaro" "apellidos" => "Hidalgo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Instituto Max Weber, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Departamento de Economía, Universidad de Castilla la Mancha, Toledo, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Coste-efectividad de una unidad monográfica de asma" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1480 "Ancho" => 1638 "Tamanyo" => 161525 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Cost effectiveness of AC treatment vs standard outpatient services. Study findings and threshold ICER.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">According to a report published by the World Health Organization, 300 million people worldwide suffered from asthma in 2004, and its prevalence continues to rise.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">1</span></a> In Spain, around 5% of the adult population are affected by the disease.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">2</span></a> Despite therapeutic advances and the implementation of clinical practice guidelines,<a class="elsevierStyleCrossRefs" href="#bib0170"><span class="elsevierStyleSup">3,4</span></a> the disease is poorly controlled in between 50% and 70% of asthma sufferers.<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">5,6</span></a> A recent Spanish report found that in 3.9% of asthmatics, the disease is severe and poorly controlled.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">7</span></a> The AsmaCost<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">8</span></a> study estimated the annual cost per asthma patient at €2635, with 50% of this due to severe cases.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">9</span></a> The 2004 COAX study estimated the mean cost of a moderate asthma exacerbation at €1230, and a severe exacerbation at €3543.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">10</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">These figures show the need for strategies aimed at improving follow-up of asthma patients and their interaction with specialist physicians, coupled with a more personalized approach in which individual patient needs are recognized and pharmacological or behavioral (education and follow-up of therapeutic compliance) interventions undertaken.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">11</span></a> All these strategies should be spearheaded by asthma clinics (AC). These outpatient services, staffed by multidisciplinary teams and headed by an expert in the disease would not only provide a comprehensive service, but also play a major role in optimizing economic resources. Nevertheless, previous studies have failed to assess the cost effectiveness of a specialized asthma clinic for both patients and the health service.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Materials and Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Design</span><p id="par0015" class="elsevierStylePara elsevierViewall">Retrospective, observational, crossover study with the primary objective of evaluating the cost effectiveness of managing individuals diagnosed with asthma seen for the first time in 2012 in the Hospital Universitario Lucus Augusti (HULA) AC in Lugo, Spain.</p><p id="par0020" class="elsevierStylePara elsevierViewall">The HULA AC (which was opened in 2010) comprises 2 consulting areas (medical and nursing) staffed by asthma specialists. The multidisciplinary team also includes staff from the allergy and immunology clinic. The AC performs all the tests and studies required for the diagnosis and follow-up of asthma patients (spirometry, plethysmography, oscillometry, fractional exhaled nitric oxide, methacholine and mannitol challenge, sputum cell count, etc.) Patients with exacerbations are treated during normal working hours in the pulmonology day clinic, where biological therapies are administered. All patients are taught how to manage their disease and their therapy, and are given a written treatment schedule. The AC is also involved in clinical research and helps train residents and pulmonologists from all over Spain. Asthmatics are referred to the AC from primary care or other specialist centers at the discretion of their attending physician, and not exclusively due to poor disease control. According to the head of the AC, it is equally important to care for patients with well-controlled asthma (workload permitting) for 2 main reasons: to ensure correct diagnosis and to taper treatment once the disease is under control. Due to either lack of training or poor diagnostic methods, diagnosis and treatment follow-up are rarely guaranteed outside the setting of an AC.</p><p id="par0025" class="elsevierStylePara elsevierViewall">For the purpose of the study, data were sourced from IANUS, the Galician Health Service electronic medical record database, which includes details such as date of medical consultation, tests performed, and changes in therapy. “Case-period” was defined as the 365 days following the first consultation at the AC, and “control-period” was defined as the preceding 365 days. The clinical status and cost of care for each patient during the year preceding and following the first evaluation in the AC were compared.</p><p id="par0030" class="elsevierStylePara elsevierViewall">The study was approved by the Clinical Research Ethics Committee (CREC) of Galicia (code 2014/180).</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Patients</span><p id="par0035" class="elsevierStylePara elsevierViewall">The clinical records of all patients (mostly poorly controlled) aged≥18 years, previously diagnosed with asthma, and seen in the AC from 1 January 2012 to 1 January 2013, were included in the study. In some patients referred to the AC with a diagnosis of asthma, the disease was later ruled out. These patients were not followed up.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Study Protocol</span><p id="par0040" class="elsevierStylePara elsevierViewall">Details of the clinical and functional status and analytical tests performed on all study patients were extracted from IANUS, together with their use of healthcare resources (visits to primary care physicians and specialists due to exacerbations, days of hospital stay, emergency care, asthma medication and diagnostic tests performed). Other data included loss of labor productivity days due to visits to the doctor, the emergency room, and hospitalization, and the cost of traveling to the AC. All study data were uploaded to an electronic case report form (CRF) for subsequent statistical analysis.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Variables</span><p id="par0045" class="elsevierStylePara elsevierViewall">Study variables and their definitions [diagnosis of asthma, definition of control, exacerbation, cost, and quality-adjusted life year (QALY)] are summarized in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. Cost variables included direct medical costs met by the Galician regional health service (SERGAS) relating to use of resources (asthma medication, visits to the doctor, diagnostic tests and hospitalization), the cost to the patient of traveling to the AC (direct non-medical cost), and the cost to society in terms of loss of labor productivity (indirect cost) for both the year preceding and following referral to the AC. The reference year for costs was 2012. Being a 1-year follow-up study, no discount rate was applied. <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> shows the itemized cost of resources and the data source.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0050" class="elsevierStylePara elsevierViewall">Effectiveness was measured in terms of both number of patients successfully controlled and QALYs gained 1 year after treatment in the AC. Disease control was defined as a minimally symptomatic or asymptomatic (asthma control test [ACT]≥20) patient with normal or near-normal lung function (FEV<span class="elsevierStyleInf">1</span>>70% of predicted) and no exacerbations. None of the patients included in the study had completed quality of life questionnaires that would have allowed us to directly measure QALY. In order to estimate overall pre- and post-AC QALY for the series as a whole, we extrapolated QALY estimates reported in previous studies,<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">6,17,18</span></a> using the method described in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Statistical and Cost-Effectiveness Analysis</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Statistical Analysis</span><p id="par0055" class="elsevierStylePara elsevierViewall">The number of controlled/uncontrolled patients at the time of their first visit to the AC and after 1 year of follow-up by a specialist were compared. Each clinical evolution parameter was also analyzed separately (ACT test score and lung function [FEV<span class="elsevierStyleInf">1</span>] in liters and as a percentage of predicted at the first visit to the AC and after 1 year of follow-up, and the total number of exacerbations during the year preceding and following the first visit to the AC). In most cases, the <span class="elsevierStyleItalic">t</span> test for matched pairs was used to analyze the data from the same individuals at 2 different time points: point 1 (1 year preceding treatment at the AC) and point 2 (1 year following treatment at the AC). This analysis showed whether asthma management at the AC resulted in statistically significant differences in patient variables at point 1 (past status) and point 2 (current status). Non-parametric methods (for example, the Wilcoxon test) were used for non-normal distribution of certain variables. Statistical significance was set at <span class="elsevierStyleItalic">P</span><.05. Data were analyzed using SPSS (IBM SPSS Statistics for Windows, version 19.0).</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Cost-Effectiveness Analysis</span><p id="par0060" class="elsevierStylePara elsevierViewall">The incremental cost-effectiveness ratio (ICER) represents the annual incremental cost of obtaining 1 additional unit of the measure of effect if the patient is treated in the AC vs standard outpatient services. ICER is calculated using the formula: ICER<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>(<span class="elsevierStyleItalic">C</span><span class="elsevierStyleInf">2</span>−<span class="elsevierStyleItalic">C</span><span class="elsevierStyleInf">1</span>)/(<span class="elsevierStyleItalic">E</span><span class="elsevierStyleInf">2</span>−<span class="elsevierStyleItalic">E</span><span class="elsevierStyleInf">1</span>), where <span class="elsevierStyleItalic">C</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">i</span></span> and <span class="elsevierStyleItalic">E</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">i</span></span> are the total cost and total effect at point <span class="elsevierStyleItalic">i</span> (<span class="elsevierStyleItalic">i</span>=1: year preceding referral to the AC; <span class="elsevierStyleItalic">i</span>=2: year following referral to the AC). We calculated the ICER for each patient achieving disease control and the ICER per QALY gained from 2 different viewpoints: the SERGAS and the social perspective. In terms of the SERGAS, QALY considers only costs covered by the public health system (direct healthcare costs), while the social perspective includes costs met by both the patient and society (transport costs and loss of labor productivity, respectively).</p></span></span></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Results</span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Patient Demographics and Clinical and Functional Status</span><p id="par0065" class="elsevierStylePara elsevierViewall">A total of 83 patients were included in the study (mean age 48.9±15.2 years, 60.2% women). Asthma was ruled out in 9 patients (10.8%) on the basis of a methacholine challenge test performed after suspending all the patient's usual medication. The clinical and demographic characteristics of the patients are shown in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>. Considering that 80% of study patients were receiving combined inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA), and that this was unsuccessful in controlling the disease in most cases, it is reasonable to assume that most study patients presented moderate to severe asthma.</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Patient Evolution</span><p id="par0070" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a> shows the evolution of the clinical and functional status of study patients. The percentage of uncontrolled patients fell significantly (59% vs 14.5%), in parallel with an improvement in clinical parameters. The total number of visits to AC physicians (including both scheduled and spontaneous consultations), visits to the emergency room, loss of working days, and days of hospitalization were reduced (the latter, however, was not clinically significant). The few cases requiring hospitalization were admitted to the pulmonary medicine department. No patients were admitted to critical care.</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Changes in Medication After Referral to the Asthma Clinic</span><p id="par0075" class="elsevierStylePara elsevierViewall">The number of patients receiving combined ICS/LABA (from 79.5% to 41.0%) and antileukotriene (from 22.9% to 6%) therapy fell, while the number receiving monotherapy ICS, omalizumab, anticholinergics and ultraLABAs (24<span class="elsevierStyleHsp" style=""></span>h) increased. Systemic steroid therapy was suspended in all patients (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Costs</span><p id="par0080" class="elsevierStylePara elsevierViewall">Management in the AC was associated with a significant increase in the cost of medication and diagnostic tests. This was partially offset by a reduction in the number of spontaneous consultations, hospitalizations, patient-borne travel expenses, and indirect costs related to loss of productivity. Overall, management in the AC increased the total cost per patient by 51.3% (<a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a> and <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Results of the Incremental Cost-Effectiveness Analysis</span><p id="par0085" class="elsevierStylePara elsevierViewall">After receiving treatment at the AC, 37 previously uncontrolled asthmatics achieved disease control. Total overall QALYs gained for the series as a whole were 7.53 (mean of 0.09 per patient). From the perspective of the SERGAS, the ICER, which represents the incremental cost of obtaining 1 additional unit of the measure of effect, was €1680 per controlled patient per year, and €8265 per QALY gained. Social costs were €1399 and €6876, respectively. The foregoing shows the cost (SERGAS and social) of achieving disease control in 1 patient and 1 additional QALY, respectively (<a class="elsevierStyleCrossRef" href="#tbl0030">Table 6</a>).</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Discussion</span><p id="par0090" class="elsevierStylePara elsevierViewall">This study has shown that ACs can significantly improve the clinical status of asthma patients; in our series, the percentage of controlled patients increased from 41% to 86%, and ACT scores improved from a mean of 18.7 to 22.6. The latter is an important finding, since ACT scores, which measure the extent of asthma control, have been associated with quality of life in asthmatics.<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">19,20</span></a> The number of exacerbations, meanwhile, fell by 75%.</p><p id="par0095" class="elsevierStylePara elsevierViewall">All cost variables, with the exception of drugs and diagnostic tests, were significantly reduced, giving an annual saving per patient of €338. The ICER per controlled patient was €1680 for SERGAS, and €1399 for social costs. Each QALY gained by treatment received at an AC instead of in standard outpatient services represents an additional cost per year of €8256 for SERGAS, and €6876 for society. Although in Spain no official cost-effectiveness threshold has been set to determine whether or not a particular healthcare strategy should be introduced, evidence in the literature suggests that a cost of between €30<span class="elsevierStyleHsp" style=""></span>000 and €45<span class="elsevierStyleHsp" style=""></span>000/QALY is reasonable.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">21</span></a> This is in line with the recommendations of the <span class="elsevierStyleItalic">National Institute for Health and Care Excellence</span> (NICE), which establishes an ICER threshold of between £20<span class="elsevierStyleHsp" style=""></span>000 and £30<span class="elsevierStyleHsp" style=""></span>000.<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">22</span></a><a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a> shows the cost effectiveness of AC treatment vs standard care.</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">Few studies have so far evaluated the cost effectiveness of ACs in Spain. Among these, Domingo Ribas<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">23</span></a> in 2001 reported significant savings due to a reduction in the number of visits to the emergency room and hospitalizations. The sample size in this study, however, was small (20 patients), and all were steroid dependent.</p><p id="par0105" class="elsevierStylePara elsevierViewall">It is important to highlight that asthma was ruled out in 10% of our patient cohort following diagnostic tests performed in the AC. This prevalence of over-diagnosis is lower than the 30% previously reported in the literature,<a class="elsevierStyleCrossRefs" href="#bib0275"><span class="elsevierStyleSup">24,25</span></a> possibly because many asthmatics had already been seen by a specialist prior to referral to the AC. It is also interesting to observe a significant reduction in combination ICS/LABA therapy in our cohort, following the recommendation of asthma guidelines, while the use of other drugs increased, like anticholinergics, inhaled steroids in monotherapy, and omalizumab, which is also in line with guidelines. If we had followed the example of other studies<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">25</span></a> and estimated the cost of drugs over the patient's lifetime (adjusted to the life expectancy), savings in the cost of therapy would have been higher.</p><p id="par0110" class="elsevierStylePara elsevierViewall">The higher cost of caring for asthmatics in the AC is mainly due to the cost of drugs, particularly omalizumab. This drug was used by 6% of AC patients, and increased costs by 60%. However, following asthma guidelines, omalizumab is only used in patients with severe asthma that fail to respond to inhaled treatment. The cost effectiveness of this therapy has been shown in previous studies conducted in countries with different healthcare systems.<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">17,26–29</span></a> In Spain, a study in omalizumab reported an incremental cost of €462 per prevented exacerbation, and €26<span class="elsevierStyleHsp" style=""></span>864 per QALY gained in patients receiving this therapy.<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">30</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">This study has some obvious limitations. Although it is retrospective, it was conducted after full implementation of the electronic medical record system in Galicia. This ensures that information referring to changes in medication, visits to primary care, the emergency room and specialists, and sick leave are fully updated. In addition, all our patients were seen by a single specialist, thus reducing variations in clinical practice to a minimum. It is important to note that this study was conducted exclusively in a hospital setting, because treatment indications for patients not strictly catered for in clinical practice guidelines could be interpreted differently in different ACs (for example, reducing a patient's treatment or deciding which patients should receive a monoclonal antibody or a LAMA). This is a factor that could affect both the cost and effectiveness of the therapy. Although our sample size was relatively small, each patient was carefully followed-up from the AC. Furthermore, although the crossover design guarantees good pairing (each patient is self-paired), it is limited insofar as it is impossible to completely avoid possible confounding factors in the control period (prior to referral to the AC). This is because aspects such as therapeutic compliance, possible visits to a private specialist, etc., cannot be taken into account. In any event, we believe that the potential impact of seasonal confounding factors (exposure to allergens, viruses, etc.) was avoided by selecting a 12-month follow-up period, and that our detailed examination of medical records guarantees that both control and case periods were comparable in all cases.</p><p id="par0120" class="elsevierStylePara elsevierViewall">The estimation of indirect costs is open to inaccuracies because loss of asthma-related labor productivity is calculated on the basis of the duration of an exacerbation and days of hospital stay, but does not take into account days worked despite asthma symptoms that could undermine performance in the workplace. Likewise, we had no reliable data relating to the real number of days lost to sick leave in each patient. Ojeda and Sanz de Burgoa<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">31</span></a> estimated asthma-related loss of labor productivity in Spain, including days worked despite asthma symptoms, to amount to €258.81/month/patient. This is significantly higher than our findings in routine clinical practice (€149.5/year). This means that the real magnitude of potential savings in terms of loss of productivity is underestimated in our study, which would in turn considerably improve the social ICER.</p><p id="par0125" class="elsevierStylePara elsevierViewall">In conclusion, the introduction of an AC in a healthcare catchment area would bring considerable benefits to patients (the percentage of well-controlled asthmatics would increase in parallel with a decrease in the number of exacerbations), and be extremely cost effective. Healthcare authorities should consider these findings when choosing the best measures to improve treatment and management of asthma patients. The creation of specialized asthma clinics is both reasonable and beneficial in terms of streamlining healthcare and improving patient outcomes.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Funding</span><p id="par0130" class="elsevierStylePara elsevierViewall">This study was sponsored by <span class="elsevierStyleGrantSponsor" id="gs1">Novartis</span>.</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Authorship</span><p id="par0135" class="elsevierStylePara elsevierViewall">All the authors contributed equally to drafting the manuscript and reviewing the content, and all have approved the final version. LPLL, RV and MM had full access to the data and are responsible for the integrity and the accuracy of the statistical analysis.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Study concept and design: LPLL, AH, and RV.</p><p id="par0145" class="elsevierStylePara elsevierViewall">Data extraction: LPLL, MCGN, and CM.</p><p id="par0150" class="elsevierStylePara elsevierViewall">Data analysis and interpretation: MM, LPLL, RV, and AH.</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Conflict of Interest</span><p id="par0155" class="elsevierStylePara elsevierViewall">Dr Pérez de Llano has received fees for consultancy and for speaking at conferences or symposiums organized by the following laboratories: Novartis, GSK, Astra, Boehringer, Ferrer, TEVA, Mundipharma, Pfizer, Boehringer, Chiesi, and Rovi. The other authors declare they have no conflict of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres624891" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec638206" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres624890" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec638207" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Materials and Methods" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Design" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Patients" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Study Protocol" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Variables" ] 4 => array:3 [ "identificador" => "sec0035" "titulo" => "Statistical and Cost-Effectiveness Analysis" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Statistical Analysis" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Cost-Effectiveness Analysis" ] ] ] ] ] 6 => array:3 [ "identificador" => "sec0050" "titulo" => "Results" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0055" "titulo" => "Patient Demographics and Clinical and Functional Status" ] 1 => array:2 [ "identificador" => "sec0060" "titulo" => "Patient Evolution" ] 2 => array:2 [ "identificador" => "sec0065" "titulo" => "Changes in Medication After Referral to the Asthma Clinic" ] 3 => array:2 [ "identificador" => "sec0070" "titulo" => "Costs" ] 4 => array:2 [ "identificador" => "sec0075" "titulo" => "Results of the Incremental Cost-Effectiveness Analysis" ] ] ] 7 => array:2 [ "identificador" => "sec0080" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0085" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0090" "titulo" => "Authorship" ] 10 => array:2 [ "identificador" => "sec0095" "titulo" => "Conflict of Interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-02-25" "fechaAceptado" => "2015-09-20" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec638206" "palabras" => array:5 [ 0 => "Asthma" 1 => "Cost effectiveness" 2 => "Management" 3 => "Asthma clinic" 4 => "Quality of life" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec638207" "palabras" => array:5 [ 0 => "Asma" 1 => "Coste-efectividad" 2 => "Control" 3 => "Unidad monográfica" 4 => "Calidad de vida" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Asthma clinics (AC) are hospital outpatient services specializing in the management of asthma. In this study, we analyzed the impact of these clinics on asthma management and their cost effectiveness in comparison with standard outpatient services.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A case–crossover study in which all new patients seen in the AC of Lugo in 2012 were included. The case period was defined as one year following the first visit to the AC; the control period was defined as the preceding year. We calculated changes in clinical quality indicators for asthma management, and estimated the incremental cost-effectiveness ratio (ICER) for each additional patient treated and for each quality-adjusted life year (QALY).</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">The number of patients (<span class="elsevierStyleItalic">n</span>=83, mean age 49±15.2<span class="elsevierStyleHsp" style=""></span>years; 60.2% women) managed in the AC increased from 41% to 86%. The asthma control test score increased from 18.7±4.6 to 22.6±2.3 (<span class="elsevierStyleItalic">P</span><.05) and FEV<span class="elsevierStyleInf">1</span> increased from 81.4±17.5% to 84.4±16.6% (<span class="elsevierStyleItalic">P</span><.05). The number of exacerbations, hospitalizations and visits for accident and emergency fell by 75%. The number of patients given combination LABA+ICS therapy fell from 79.5% to 41%. The use of other drug therapies increased as the following: anticholinergics, from 3.6% to 16.9%; ICS in monotherapy, from 3.6% to 45.8%; and omalizumab, from 0% to 6%. ICERs per patient managed and per QALY gained were €1399 and €6876, respectively (social perspective).</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Treatment in ACs is cost effective and beneficial in asthma management.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introducción</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Las unidades monográficas de asma (UMA) son consultas hospitalarias implementadas para lograr una mejoría clínica de los pacientes. Este estudio analiza su impacto sobre el control del asma y su coste-efectividad en comparación con las consultas ordinarias.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Estudio de casos cruzados que incluyó a todos los pacientes que fueron atendidos por primera vez en la UMA de Lugo durante 2012. Se definió el «periodo-caso» como los 365<span class="elsevierStyleHsp" style=""></span>días que siguieron a la primera visita en la UMA, y el «periodo-control» como los 365<span class="elsevierStyleHsp" style=""></span>días que la antecedieron. Se calcularon los cambios en indicadores clínicos relevantes para el control del asma y se estimó la relación de coste-efectividad incremental (RCEI) por cada paciente adicional que fue controlado y por cada año de vida ajustado por calidad (AVAC).</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">El porcentaje de pacientes (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>83, edad media 49<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>15,2<span class="elsevierStyleHsp" style=""></span>años; 60,2% mujeres) controlados aumentó del 41 al 86%. El resultado del test de control del asma mejoró desde 18,7<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>4,6 hasta 22,6<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2,3 (p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0,05) y el FEV<span class="elsevierStyleInf">1</span> se elevó desde 81,4%<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>17,5 hasta 84,4%<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>16,6 (p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0,05). Las exacerbaciones, hospitalizaciones y visitas a urgencias disminuyeron un 75, un 78 y un 75%, respectivamente. La utilización de combinaciones CI/LABA decreció del 79,5% al 41%. El uso de otros fármacos aumentó: anticolinérgicos del 3,6 al 16,9%, CI en monoterapia del 3,6 al 45,8%, y omalizumab del 0 al 6%. Las RCEI por paciente controlado y por AVAC ganado fueron de 1.399 y 6.876<span class="elsevierStyleHsp" style=""></span>€, respectivamente (perspectiva social).</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">La atención en una UMA es coste-efectiva y tiene un impacto beneficioso sobre el control del asma.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0050">Please cite this article as: Pérez de Llano LA, Villoro R, Merino M, Neira MdCG, Muñiz C, Hidalgo Á. Coste-efectividad de una unidad monográfica de asma. Arch Bronconeumol. 2016;52:196–203.</p>" ] ] "multimedia" => array:9 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1027 "Ancho" => 3161 "Tamanyo" => 147838 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Percentage of patients and therapies received 1 year before and 1 year after referral to the AC.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1379 "Ancho" => 3126 "Tamanyo" => 204964 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Annual cost per patient (€) 1 year before and 1 year after referral to the AC.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1480 "Ancho" => 1638 "Tamanyo" => 161525 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Cost effectiveness of AC treatment vs standard outpatient services. Study findings and threshold ICER.</p>" ] ] 3 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">AC, asthma center; ACT, asthma control test; DOGA, official gazette of Galicia; FENO, fractional exhaled nitric oxide; FEV<span class="elsevierStyleInf">1</span>, forced expiratory volume in 1<span class="elsevierStyleHsp" style=""></span>s; GEMA, Spanish asthma management guidelines; HULA, Hospital Universitario Lucus Augusti, Lugo; HRQL, health-related quality of life; IANUS, electronic medical record system used by SERGAS; IgE, immunoglobulin E; QALY, quality-adjusted life years; SERGAS, Galician regional health service.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Definition \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">Previous asthma diagnosis</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Patient diagnosed with and treated for asthma before referral to the HULA AC. This diagnosis could be ruled out by the AC specialist on the basis of a methacholine challenge test. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">Asthma</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Clinical diagnosis of asthma and positive results on at least 1 GEMA-approved objective diagnostic test (positive bronchodilator test, positive bronchial challenge test, FENO>30<span class="elsevierStyleHsp" style=""></span>ppb).<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">4</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">Controlled asthma</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Minimally symptomatic or asymptomatic patient (ACT≥20), with normal or near-normal lung function (FEV<span class="elsevierStyleInf">1</span>>70% predicted), and no exacerbations. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleBold">Asthma exacerbation</span><a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">12</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Severe</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Events that require administration of systemic steroids or an increase in the existing dose for at least 3 days (if the 2 courses of steroids are separated by at least 1 week, the exacerbation is considered separate). Visit to the emergency room and hospitalization with administration of steroids. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Moderate</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Deterioration in the patient's symptoms beyond the usual range of day-to-day asthma variations, requiring a change in the patient's usual medication, but which is not severe. Visits to the emergency room not requiring administration of steroids. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleBold">Costs</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Direct medical costs</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Costs met directly by the regional healthcare authority. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Drugs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Difference between the total cost of asthma drugs during the month preceding evaluation by the AC asthma specialist (based on the cost shown in the electronic prescription) and the total cost of the drugs administered during the last month of the 12-month period following evaluation in the AC. The difference was extrapolated to 12 months to account for changes in the price of the drugs over the study year. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Visits to the doctor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The cost of each visit (primary care physician, day hospital, specialist, or emergency room) taken from the official regional gazette (DOGA) for 2012.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">13</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Hospital admission \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The cost of each day of hospitalization was taken from the official regional gazette (DOGA). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Diagnostic tests \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The cost of functional tests (spirometry with or without bronchodilator, FENO and methacholine challenge), analytical tests (complete blood count, IgE, blood gases), skin prick test panels and radiological studies were taken from the DOGA. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Direct non-medical costs</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Direct non-medical costs are those met directly by the patient or their family members in connection with the disease or obtaining medical care (e.g., travel expenses met by the patient, services provided by professional carers, alternative therapies). In this study, only travel expenses met by the patient are included. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Travel expenses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Average cost to the patient of traveling from their place of residence to the AC or health center to receive treatment for asthma (emergencies or scheduled consultations). A cost of €0.19/km was established, based on the allowance set by the Ministry of the Economy for the use of personal vehicles.<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">14</span></a> This per/km rate was multiplied by the mileage shown in the IANUS (Galician Health Service electronic medical record database). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Indirect costs</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Economic assessment of the losses incurred by society due to the disease. In general terms, this includes loss of labor productivity by the patient or their family members, if these latter are in charge of caring for the patient. In this study, only a rough estimate of loss of labor productivity by the patient is included. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Loss of labor productivity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Mean cost of absenteeism among asthmatic employees due to visits to the doctor and hospitalization. The cost per day of absenteeism was calculated using the human capital model, under which the loss of daily productivity is measured in monetary terms on the basis of the mean wage earned in 1 day.<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">15</span></a> In this study, gross average wages in the region of Galicia, bracketed by age and sex, were taken form the Wage Structure Survey conducted by the Spanish Institute of Statistics.<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">16</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Total costs</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The sum of direct medical costs, direct non-medical costs and indirect costs. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">Quality-adjusted life years (QALY)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">QALYs measure health-related quality of life (HRQL) on a scale of 0 to 1, where 1 represents 1 year with the best possible health status. They are calculated on the basis of the patient's self-perceived health status. In this study, QALYs in pre- and post-AC referral patients were based on the estimations made by Doz et al.,<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">6</span></a> who attributed 0.89 and 0.69 QALYs to controlled and uncontrolled patients, respectively. Following this, the corresponding QALYs were adjusted for decrease in HRQL for each day with exacerbation over a 12-month period. This was based on NICE estimations that each day with exacerbation not requiring hospitalization costs the patient 0.002 QALYs, and each day with exacerbation requiring hospitalization costs 0.001 QALYs.<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">17,18</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1024951.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Definition of Study Variables.</p>" ] ] 4 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Cost (€) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Source \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Diagnostic tests (cost per test)</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Spirometry \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Post-BD spirometry \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">80 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>FENO \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Methacholine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Chest X-ray \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>CT scan \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">120 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Blood count \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IgE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Prick test \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Drugs (monthly cost of treatment)</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Salmeterol “200/100”/“500/100”/“1000/100” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fluticasone 45/61/83 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Budesonide “160/4,5”/“160/9”/“320/9”/“620/18”/“640/18”/“160/4.5” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Formoterol 16/51/32/128/64/16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Beclometasone “100/6”/“200/10”/“400/24” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Formoterol 12.5/25/51 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Fluticasone “200”/“1000”/“2000” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16/52/104 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Budesonide “200”/“400”/“800” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5/8/19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Indacaterol 150 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Tiotropium 18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Glycopyrronium \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Montelukast 10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Mometasone “200”/“400” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15/26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Nasal Mometasone “200”/“200” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Fluticasone inhaler “55”/“110”/“200” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.25/6.5/13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Deflazacort “6”/“30” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9/45 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Omalizumab “150”/“300”/“450”/“900”/“1200” \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">355/710/1065/1420/2840 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Medical services (cost per service)</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Primary care consultation (follow-up consultation) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">34.45 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">d</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Emergency room \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">359.79 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">d</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Days of hospital stay \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">526.32 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">d</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Travel expenses (patient, cost per km)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">e</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Loss of labor productivity (mean daily wage)</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Under 25 years (women/men) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25.54/30.47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">f</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>From 25 to 34 years (women/men) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">40.41/50.05 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">f</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>From 35 to 44 years (women/men) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">51.24/66.80 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">f</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>From 55 to 54 years (women/men) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">46.73/61.29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">f</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>55 years and older (women/men) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">51.61/67.33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">f</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1024956.png" ] ] ] "notaPie" => array:6 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Puente Maestú L, García de Pedro J. Las pruebas funcionales respiratorias en las decisiones clínicas. Arch Bronconeumol. Mayo de 2012;48(5):161–9.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Official rates established in the Hospital Universitario Lucus Augusti (Lugo).</p>" ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Price shown on the electronic prescription, taken from IANUS.</p>" ] 3 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "d" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Decreto 221/2012 (31 de octubre), por el que se establecen las tarifas de los servicios sanitarios prestados en los centros dependientes del Servicio Gallego de Salud y en las fundaciones públicas sanitarias. Available from: <a class="elsevierStyleInterRef" id="intr0005" href="http://www.xunta.es/dog/Publicados/2012/20121121/AnuncioC3K1-091112-0002_es.html">http://www.xunta.es/dog/Publicados/2012/20121121/AnuncioC3K1-091112-0002_es.html</a>.</p>" ] 4 => array:3 [ "identificador" => "tblfn0025" "etiqueta" => "e" "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Orden EHA/3770/2005 (1 de diciembre), por la que se revisa el importe de la indemnización por uso de vehículo particular establecida en el Real Decreto 462/2002 (24 de mayo), sobre indemnizaciones por razón del servicio. Available on: <a class="elsevierStyleInterRef" id="intr0010" href="http://www.boe.es/boe/dias/2005/12/03/pdfs/A39852-39852.pdf">http://www.boe.es/boe/dias/2005/12/03/pdfs/A39852-39852.pdf</a>.</p>" ] 5 => array:3 [ "identificador" => "tblfn0030" "etiqueta" => "f" "nota" => "<p class="elsevierStyleNotepara" id="npar0030">Encuesta Anual de Estructura Salarial. Serie 2008-2012. Resultados para Galicia: Ganancia media anual por trabajador según sexo y edad. Available from: <a class="elsevierStyleInterRef" id="intr0015" href="http://www.ine.es/jaxi/tabla.do?path=/t22/p133/cno11/serie/l0/%26file=03004.px%26type=pcaxis%26L=0">http://www.ine.es/jaxi/tabla.do?path=/t22/p133/cno11/serie/l0/&file=03004.px&type=pcaxis&L=0</a>.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Itemized Costs and Sources.</p>" ] ] 5 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">ABPA, allergic bronchopulmonary aspergillosis; ASA, acetylsalicylic acid; GERD, gastrointestinal reflux disease; IgE, immunoglobulin E; SAHS, sleep apnea hypopnea syndrome; SD, standard deviation.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Age (mean±SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">48.9±15.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sex: women<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">50 (60.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Confirmation of asthma diagnosis<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">74 (89.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Onset of asthma: early (<12 years)/late<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 (27.7)/60 (72.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Positive prick test<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33 (41.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">IgE: UI/ml (mean±SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">326±907 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Eosinophils: number/mm<span class="elsevierStyleSup">3</span> (mean±SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">463±402 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Rhinitis<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">55 (66.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sinusitis<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">21 (25.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Polyposis<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11 (13.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">ASA intolerance<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 (8.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">ABPA<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 (2.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">GERD<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17(20.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Obesity<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33 (39.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SAHS<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 (4.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Vocal cord dysfunction<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 (1.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Smoking<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 (12.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Anxiety<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17 (20.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Depression<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 (14.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Positive bronchial challenge<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">35 (44.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Positive methacholine challenge: yes/no/not performed<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 (9.6)/12 (14.5)/63 (75.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">FENO>30<span class="elsevierStyleHsp" style=""></span>ppd<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">52 (62.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1024952.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0035" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0035">Number of positive cases and percentage (%) of total.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Patient Demographics and Clinical Characteristics (<span class="elsevierStyleItalic">n</span>=83).</p>" ] ] 6 => array:7 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">ACT, asthma control test; FEV<span class="elsevierStyleInf">1</span>, forced expiratory volume in 1<span class="elsevierStyleHsp" style=""></span>s; SD, standard deviation.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variables \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Preceding Year \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Following Year \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">FEV<span class="elsevierStyleInf">1</span> (l) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.5±0.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.6±0.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.05 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">FEV<span class="elsevierStyleInf">1</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">81.4±17.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">84.4%±16.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.05 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">ACT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18.7±4.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">22.6±2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Exacerbations/patient \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.8±1.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.2±0.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Control: yes/no (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">41.0/59.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">85.5/14.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Visits to doctor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.9±2.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.2±1.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Visits to emergency room \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.4±1.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.1±0.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.05 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Days of hospitalization \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.11±0.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.02±0.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">.102 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Working days lost \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.9±6.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.3±1.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.05 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1024953.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Clinical and Functional Evolution (Mean±SD).</p>" ] ] 7 => array:7 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Anti-IgE, anti-immunoglobulin E; ICS/LABA, inhaled corticosteroids with long-acting beta-agonists; UltraLABA, beta-agonists lasting 24<span class="elsevierStyleHsp" style=""></span>h.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Preceding Year (Mean±SD) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Following Year (Mean±SD) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variation (%) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">A. Direct medical costs</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1008±959 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1757±4662 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">+74.2% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">.634 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">a) Visits to doctor, hospitalizations and emergencies</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">260±669 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">57±432 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−78.1% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">b) Diagnostic tests</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">98±94 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">208±72 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">+112.8% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="5" align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">c) Drugs</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Combination ICS/LABA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">46.24±36.29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">22.19±31.15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−52% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Anticholinergics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.77±9.20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8.19±18.30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">+462.6% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.05 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Inhaled steroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.72±4.09 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10.86±17.36 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">+1501.7% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>UltraLABA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.00±0.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4.82±14.85 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">− \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.05 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Leukotriene antagonists \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4.81±8.88 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.27±5.03 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−73.7% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Oral steroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.65±5.03 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.00±0.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">.180 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Anti-IgE (omalizumab) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.00±0.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">77±372.11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">− \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.05 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Total drugs</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">650</span>±<span class="elsevierStyleItalic">518</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">1492</span>±<span class="elsevierStyleItalic">4630</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleItalic">+129.4%</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleItalic">.592</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">B. Direct non-medical costs: travel expenses</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">69±191 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12±81 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−82.6% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">C. Indirect costs: loss of labor productivity</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">149.5±289.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">71.3±76.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−52.3% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><.05 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Total cost per patient</span> (A+B+C) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1216.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1840.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">+51.3% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">.296 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1024954.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">Changes in Annual Costs per patient (€).</p>" ] ] 8 => array:7 [ "identificador" => "tbl0030" "etiqueta" => "Table 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "<p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years, total for each patient group; SERGAS, Galician health service.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Preceding Year \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Following Year \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Increment \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Total direct medical costs (€)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">83<span class="elsevierStyleHsp" style=""></span>664 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">145<span class="elsevierStyleHsp" style=""></span>831 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">62<span class="elsevierStyleHsp" style=""></span>167 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Total social costs (direct medical cost, travel and loss of productivity) (€)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100<span class="elsevierStyleHsp" style=""></span>970 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">152<span class="elsevierStyleHsp" style=""></span>745 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">51<span class="elsevierStyleHsp" style=""></span>775 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Controlled patients</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">34 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">71 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">37 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>QALY in the controlled patient group \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">30.25 (<span class="elsevierStyleItalic">n</span>=34) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">63.18 (<span class="elsevierStyleItalic">n</span>=71) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">32.93 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>QALY in the uncontrolled patient group \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33.65 (<span class="elsevierStyleItalic">n</span>=49) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8.25 8 (<span class="elsevierStyleItalic">n</span>=12) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">−25.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Total QALY (n</span>=<span class="elsevierStyleItalic">83)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">63.89 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">71.42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.53 (<span class="elsevierStyleItalic">P</span><.001) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">ICER from SERGAS perspective</span><a class="elsevierStyleCrossRef" href="#tblfn0040"><span class="elsevierStyleSup">a</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>ICER per controlled patient \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1680 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>ICER per QALY gained \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8256 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">ICER in terms social costs</span><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">b</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>ICER per controlled patient \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1399 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>ICER per QALY gained \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6876 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1024955.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0040" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0040">The SERGAS perspective only takes into account the increase in direct medical costs.</p>" ] 1 => array:3 [ "identificador" => "tblfn0045" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0045">The social perspective takes into account the increase in overall social costs (medical, travel and loss of labor productivity).</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">Cost-Effectiveness Analysis.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:31 [ 0 => array:3 [ "identificador" => "bib0160" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach [Internet]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "WHO" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2007" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0165" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Identificación y tratamiento de individuos con criterios epidemiológicos de asma en adultos jóvenes de cinco áreas españolas. Grupo Español del Estudio Europeo del Asma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Martínez-Moratalla" 1 => "E. Almar" 2 => "J. Sunyer" 3 => "J. Ramos" 4 => "A. Pereira" 5 => "F. Payo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "1999" "volumen" => "35" "paginaInicial" => "223" "paginaFinal" => "228" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10378050" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0170" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "From the Global Strategy for Asthma Management and Prevention [Internet]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Global Initiative for Asthma (GINA)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2014" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0175" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Guía Española para el Manejo del Asma (GEMA). [Internet]. Available from: <a id="intr0035" class="elsevierStyleInterRef" href="http://www.gemasma.com/">http://www.gemasma.com/</a> [accessed 17.11.14]." ] ] ] 4 => array:3 [ "identificador" => "bib0180" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P. Demoly" 1 => "K. Annunziata" 2 => "E. Gubba" 3 => "L. Adamek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00008111" "Revista" => array:6 [ "tituloSerie" => "Eur Respir Rev" "fecha" => "2012" "volumen" => "21" "paginaInicial" => "66" "paginaFinal" => "74" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22379176" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0185" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The association between asthma control, health care costs, and quality of life in France and Spain" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Doz" 1 => "C. Chouaid" 2 => "L. Com-Ruelle" 3 => "E. Calvo" 4 => "M. Brosa" 5 => "J. Robert" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2466-13-15" "Revista" => array:5 [ "tituloSerie" => "BMC Pulm Med" "fecha" => "2013" "volumen" => "13" "paginaInicial" => "15" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23517484" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0190" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Quirce" 1 => "V. Plaza" 2 => "C. Picado" 3 => "M. Vennera" 4 => "J. Casafont" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Investig Allergol Clin Immunol" "fecha" => "2011" "volumen" => "21" "paginaInicial" => "466" "paginaFinal" => "471" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21995180" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0195" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coste económico del paciente asmático en España (estudio AsmaCost)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Martínez-Moragón" 1 => "J. Serra-Batllés" 2 => "A. de Diego" 3 => "M. Palop" 4 => "P. Casan" 5 => "C. Rubio-Terrés" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arbres.2009.04.006" "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2009" "volumen" => "45" "paginaInicial" => "481" "paginaFinal" => "486" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19525051" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0200" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Costs of asthma according to the degree of severity" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Serra-Batlles" 1 => "V. Plaza" 2 => "E. Morejón" 3 => "A. Comella" 4 => "J. Brugués" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "1998" "volumen" => "12" "paginaInicial" => "1322" "paginaFinal" => "1326" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9877485" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0205" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost and management of asthma exacerbations in Spanish hospitals (COAX study in hospital services)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Borderías Clau" 1 => "M. Zabaleta Murguionda" 2 => "J.A. Riesco Miranda" 3 => "C. Pellicer Ciscar" 4 => "J.R. Hernández Hernández" 5 => "T. Carrillo Díaz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2005" "volumen" => "41" "paginaInicial" => "313" "paginaFinal" => "321" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15989888" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0210" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Why aren’t we doing better in asthma: time for personalised medicine?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Thomas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/npjpcrm.2015.4" "Revista" => array:5 [ "tituloSerie" => "NPJ Prim Care Respir Med" "fecha" => "2015" "volumen" => "25" "paginaInicial" => "15004" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25741858" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0215" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.K. Reddel" 1 => "D.R. Taylor" 2 => "E.D. Bateman" 3 => "L.-P. Boulet" 4 => "H.A. Boushey" 5 => "W.W. Busse" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200801-060ST" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2009" "volumen" => "180" "paginaInicial" => "59" "paginaFinal" => "99" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19535666" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0220" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Decreto do DOG no. 222 do 2012/11/21 - Xunta de Galicia [Internet]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Diario Oficial de Galicia (DOGA)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2012" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0225" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "BOE núm. 286 [Internet]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Ministerio de Economía y Hacienda" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2005" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0230" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chapter 7: The human capital model" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Grossman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:4 [ "titulo" => "Handbook of Health Economics [Internet]" "paginaInicial" => "347" "paginaFinal" => "408" "serieFecha" => "2000" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0235" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Encuesta anual de estructura salarial [Internet]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Instituto Nacional de Estadística" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2012" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0240" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201). [Internet]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "National Institute for Health Care Excellence (NICE)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2013" "editorial" => "NICE Technology Appraisal Guidance 278" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0245" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Lloyd" 1 => "D. Price" 2 => "R. Brown" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3132/pcrj.2007.00002" "Revista" => array:6 [ "tituloSerie" => "Prim Care Respir J" "fecha" => "2007" "volumen" => "16" "paginaInicial" => "22" "paginaFinal" => "27" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17297523" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0250" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The relationship between asthma-specific quality of life and asthma control" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Schatz" 1 => "D.M. Mosen" 2 => "M. Kosinski" 3 => "W.M. Vollmer" 4 => "D.J. Magid" 5 => "E. O’Connor" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/02770900701364296" "Revista" => array:6 [ "tituloSerie" => "J Asthma" "fecha" => "2007" "volumen" => "44" "paginaInicial" => "391" "paginaFinal" => "395" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17613636" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0255" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of asthma control with health care utilization and quality of life" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W.M. Vollmer" 1 => "L.E. Markson" 2 => "E. O’Connor" 3 => "L.L. Sanocki" 4 => "L. Fitterman" 5 => "M. Berger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.160.5.9902098" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "1999" "volumen" => "160" "paginaInicial" => "1647" "paginaFinal" => "1652" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10556135" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0260" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E.D. Cock" 1 => "M. Miravitlles" 2 => "J.R. González-Juanatey" 3 => "J.R. Azanza-Perea" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "PharmacoEconomics" "fecha" => "2007" "volumen" => "4" "paginaInicial" => "97" "paginaFinal" => "107" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0265" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The NICE cost-effectiveness threshold: what it is and what that means" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. McCabe" 1 => "K. Claxton" 2 => "A.J. Culyer" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "PharmacoEconomics" "fecha" => "2008" "volumen" => "26" "paginaInicial" => "733" "paginaFinal" => "744" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18767894" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0270" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness and efficiency of an outpatient clinic for corticosteroid-dependent asthmatics" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "C. Domingo Ribas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2001" "volumen" => "37" "paginaInicial" => "274" "paginaFinal" => "280" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11412525" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0275" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Confirmation of asthma in an era of overdiagnosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "V.P. Luks" 1 => "K.L. Vandemheen" 2 => "S.D. Aaron" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00165109" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2010" "volumen" => "36" "paginaInicial" => "255" "paginaFinal" => "260" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20075050" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0280" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "(Correcting) misdiagnoses of asthma: a cost effectiveness analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Pakhale" 1 => "A. Sumner" 2 => "D. Coyle" 3 => "K. Vandemheen" 4 => "S. Aaron" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2466-11-27" "Revista" => array:5 [ "tituloSerie" => "BMC Pulm Med" "fecha" => "2011" "volumen" => "11" "paginaInicial" => "27" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21605395" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0285" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "F. Van Nooten" 1 => "S. Stern" 2 => "G.-J. Braunstahl" 3 => "C. Thompson" 4 => "M. Groot" 5 => "R.E. Brown" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3111/13696998.2012.756398" "Revista" => array:6 [ "tituloSerie" => "J Med Econ" "fecha" => "2013" "volumen" => "16" "paginaInicial" => "342" "paginaFinal" => "348" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23216016" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0290" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Dewilde" 1 => "F. Turk" 2 => "M. Tambour" 3 => "T. Sandström" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1185/030079906X132389" "Revista" => array:6 [ "tituloSerie" => "Curr Med Res Opin" "fecha" => "2006" "volumen" => "22" "paginaInicial" => "1765" "paginaFinal" => "1776" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16968580" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0295" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "R.W. Costello" 1 => "D.A. Long" 2 => "S. Gaine" 3 => "T. Mc Donnell" 4 => "J.J. Gilmartin" 5 => "S.J. Lane" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11845-011-0716-2" "Revista" => array:6 [ "tituloSerie" => "Ir J Med Sci" "fecha" => "2011" "volumen" => "180" "paginaInicial" => "637" "paginaFinal" => "641" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21557095" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0300" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.W. Dal Negro" 1 => "S. Tognella" 2 => "L. Pradelli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/02770903.2012.717659" "Revista" => array:6 [ "tituloSerie" => "J Asthma" "fecha" => "2012" "volumen" => "49" "paginaInicial" => "843" "paginaFinal" => "848" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22954018" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0305" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A.N. Levy" 1 => "A. García" 2 => "A.J. Ruiz" 3 => "N. García-Agua Soler" 4 => "M.V.H. Sanjuan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/02770903.2014.941474" "Revista" => array:6 [ "tituloSerie" => "J Asthma" "fecha" => "2015" "volumen" => "52" "paginaInicial" => "205" "paginaFinal" => "210" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24995661" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0310" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Costs associated with workdays lost and utilization of health care resources because of asthma in daily clinical practice in Spain" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Coste Asma Study" "etal" => false "autores" => array:2 [ 0 => "P. Ojeda" 1 => "V. Sanz de Burgoa" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Investig Allergol Clin Immunol" "fecha" => "2013" "volumen" => "23" "paginaInicial" => "234" "paginaFinal" => "241" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23964552" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15792129/0000005200000004/v2_201604010234/S1579212916000343/v2_201604010234/en/main.assets" "Apartado" => array:4 [ "identificador" => "9374" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15792129/0000005200000004/v2_201604010234/S1579212916000343/v2_201604010234/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212916000343?idApp=UINPBA00003Z" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 1 | 3 | 4 |
| 2024 October | 52 | 36 | 88 |
| 2024 September | 43 | 32 | 75 |
| 2024 August | 61 | 45 | 106 |
| 2024 July | 59 | 33 | 92 |
| 2024 June | 63 | 27 | 90 |
| 2024 May | 130 | 42 | 172 |
| 2024 April | 49 | 39 | 88 |
| 2024 March | 37 | 21 | 58 |
| 2024 February | 38 | 43 | 81 |
| 2023 June | 1 | 0 | 1 |
| 2023 April | 4 | 1 | 5 |
| 2023 March | 16 | 5 | 21 |
| 2023 February | 44 | 34 | 78 |
| 2023 January | 32 | 28 | 60 |
| 2022 December | 67 | 41 | 108 |
| 2022 November | 72 | 31 | 103 |
| 2022 October | 55 | 38 | 93 |
| 2022 September | 50 | 39 | 89 |
| 2022 August | 34 | 45 | 79 |
| 2022 July | 41 | 44 | 85 |
| 2022 June | 31 | 39 | 70 |
| 2022 May | 48 | 32 | 80 |
| 2022 April | 41 | 41 | 82 |
| 2022 March | 52 | 40 | 92 |
| 2022 February | 40 | 30 | 70 |
| 2022 January | 47 | 50 | 97 |
| 2021 December | 66 | 37 | 103 |
| 2021 November | 71 | 57 | 128 |
| 2021 October | 82 | 54 | 136 |
| 2021 September | 41 | 46 | 87 |
| 2021 August | 53 | 52 | 105 |
| 2021 July | 34 | 38 | 72 |
| 2021 June | 68 | 49 | 117 |
| 2021 May | 79 | 48 | 127 |
| 2021 April | 178 | 94 | 272 |
| 2021 March | 99 | 38 | 137 |
| 2021 February | 63 | 28 | 91 |
| 2021 January | 64 | 32 | 96 |
| 2020 December | 67 | 40 | 107 |
| 2020 November | 77 | 47 | 124 |
| 2020 October | 73 | 45 | 118 |
| 2020 September | 59 | 17 | 76 |
| 2020 August | 41 | 14 | 55 |
| 2020 July | 48 | 26 | 74 |
| 2020 June | 73 | 17 | 90 |
| 2020 May | 87 | 27 | 114 |
| 2020 April | 84 | 24 | 108 |
| 2020 March | 69 | 30 | 99 |
| 2020 February | 73 | 22 | 95 |
| 2020 January | 63 | 22 | 85 |
| 2019 December | 85 | 30 | 115 |
| 2019 November | 72 | 24 | 96 |
| 2019 October | 50 | 22 | 72 |
| 2019 September | 59 | 40 | 99 |
| 2019 August | 38 | 19 | 57 |
| 2019 July | 40 | 25 | 65 |
| 2019 June | 40 | 26 | 66 |
| 2019 May | 60 | 25 | 85 |
| 2019 April | 86 | 41 | 127 |
| 2019 March | 49 | 21 | 70 |
| 2019 February | 43 | 21 | 64 |
| 2019 January | 38 | 19 | 57 |
| 2018 December | 53 | 13 | 66 |
| 2018 November | 148 | 22 | 170 |
| 2018 October | 288 | 22 | 310 |
| 2018 September | 135 | 8 | 143 |
| 2018 May | 5 | 0 | 5 |
| 2018 April | 33 | 6 | 39 |
| 2018 March | 18 | 6 | 24 |
| 2018 February | 27 | 5 | 32 |
| 2018 January | 20 | 5 | 25 |
| 2017 December | 36 | 9 | 45 |
| 2017 November | 22 | 8 | 30 |
| 2017 October | 25 | 17 | 42 |
| 2017 September | 22 | 12 | 34 |
| 2017 August | 21 | 7 | 28 |
| 2017 July | 10 | 3 | 13 |
| 2017 June | 30 | 17 | 47 |
| 2017 May | 38 | 10 | 48 |
| 2017 April | 40 | 12 | 52 |
| 2017 March | 13 | 12 | 25 |
| 2017 February | 17 | 10 | 27 |
| 2017 January | 7 | 13 | 20 |
| 2016 December | 26 | 14 | 40 |
| 2016 November | 34 | 21 | 55 |
| 2016 October | 43 | 22 | 65 |
| 2016 September | 31 | 7 | 38 |
| 2016 August | 44 | 10 | 54 |
| 2016 July | 29 | 5 | 34 |
Show all
